SCHEMBL465004

SCHEMBL465004

CONC(N)=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL4882477 0.97
Sulfuric Acid SCHEMBL11213693 0.88 BLM (0.36)
SCHEMBL11860691 0.74
SCHEMBL6984530 0.73
Methyl Carbamate SCHEMBL788713 0.72 ALDH1A1 (0.50)
Methyl Carbamate SCHEMBL4140 0.72
SCHEMBL158332 0.71
SCHEMBL6231532 0.71
Methoxymethane SCHEMBL15238818 0.71 CRBN (0.56)
SCHEMBL9105 0.71

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 473 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119859152-A Rayleigh Lu Geli and three-step synthesis method thereof 诚达药业股份有限公司 2025-04-22 CN claimed
CN-119859135-A Rayleigh Lu Geli intermediate and preparation method thereof 浙江工业大学 2025-04-22 CN claimed
US-20230265083-A1 Heterocycle CDK Inhibitors And Their Use Thereof PRELUDE THERAPEUTICS INCORPORATED 2023-08-24 US claimed
US-20230242543-A1 CDK Inhibitors And Their Use As Pharmaceuticals PRELUDE THERAPEUTICS INCORPORATED 2023-08-03 US claimed
US-20230144528-A1 CDK Inhibitors And Their Use As Pharmaceuticals PRELUDE THERAPEUTICS, INCORPORATED 2023-05-11 US claimed
WO-2023056441-A1 CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS PRELUDE THERAPEUTICS INCORPORATED (US) 2023-04-06 WO claimed
CN-113999145-B Synthetic method of nafamostat mesylate 开封明仁药业有限公司 2023-02-03 CN claimed
CN-114786673-A CDK inhibitors and their use as medicaments 普莱鲁德疗法有限公司 2022-07-22 CN claimed
EP-4028005-A1 CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS Prelude Therapeutics, Incorporated (US) 2022-07-20 EP claimed
WO-2022035799-A1 HETEROCYCLE CDK INHIBITORS AND THEIR USE THEREOF PRELUDE THERAPEUTICS INCORPORATED (US) 2022-02-17 WO claimed
US-20090047250-A1 Methods for treating or preventing neuroinflammation or autoimmune diseases ELFORD HOWARD L 2009-02-19 US claimed
CN-101292069-A Reducing the water and water vapour absorbence and enhancing the dimensional stability of paper and paper products and use of coated paper products BASF SE (DE) 2008-10-22 CN claimed
CN-101245037-A Preparation method of oxymethylisourea acetate JUHUA GROUP CORP (CN) 2008-08-20 CN claimed
CN-101124199-A 5-substituted-2-phenylamino-benzamides as MEK inhibiting substances CHUGAI PHARMACEUTICAL CO LTD (JP) 2008-02-13 CN claimed
CN-1703307-A Method for improving the surface hardness of a wooden body using an aqueous solution of an impregnating agent BASF AG (DE) 2005-11-30 CN claimed
CN-1703308-A Method for improving the durability, dimensional stability and surface hardness of a wooden body BASF AG (DE) 2005-11-30 CN claimed
US-6410166-B1 Organic electroluminescence device doping device and organic electroluminescence device FUTABA CORPORATION (JP) 2002-06-25 US claimed
US-5610233-A AMINO RESIN CURING RESIN, ACID CATALYST EASTMAN CHEMICAL COMPANY (US) 1997-03-11 US claimed
WO-1994020580-A1 THERMOSETTING COATING COMPOSITIONS EASTMAN CHEMICAL COMPANY (US) 1994-09-15 WO claimed
US-5288820-A Comprising acetoacetate-modified polyester or acrylic polymer, amino resin crosslinker, sulfonic acid curing agent and limonene epoxides as coloration inhibitors EASTMAN KODAK COMPANY (US) 1994-02-22 US claimed